
CGON Stock Forecast & Price Target
CGON Analyst Ratings
Bulls say
CG Oncology is currently positioned for success due to its strong clinical data and upcoming catalysts, including the topline data from the registration-directed Ph.3 BOND-003 trial and the completion of the BLA filing for cretostimogene. Its unique mechanism and potential to address multiple NMIBC settings sets it apart from competitors and makes it a potential go-to treatment option. While there are some developmental risks, CG Oncology's strong potential for market-leading share and favorable safety profile justify an Outperform, Speculative Risk rating.
Bears say
CG Oncology is making slow progress with its trials and BLA filing for cretostimogene grenadenorepvec and there is a lack of decisive data to confidently support its potential value in the market. Additionally, there are potential risks such as disappointing data updates and concentration risk as a single-asset company. There is a possibility for upside following near-term catalysts, but further evidence is needed to justify a positive outlook.
This aggregate rating is based on analysts' research of CG oncology Inc and is not a guaranteed prediction by Public.com or investment advice.
CGON Analyst Forecast & Price Prediction
Start investing in CGON
Order type
Buy in
Order amount
Est. shares
0 shares